Clinical Study on Suitable Syndromes of Acupoint Application

Randomized, double-blind, placebo-controlled, multicenter clinical study on acupoint application in the treatment of postherpetic neuralgia

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2200005624

Enrollment

Unknown

Registered

2022-02-09

Start date

2022-02-09

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

postherpetic neuralgia

Interventions

Control group:placebo patch + placebo powder

Test group:Xiaozhong Zhitong plaster + traditional Chinese medicine powder

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.In line with the diagnostic criteria of postherpetic neuralgia ; 2. 2. VAS = 4 points ; 3. Age 18-75 years ; 4. Course of disease > 30 days, = 180 days 5. Patients and their families sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with liver and kidney failure ; 2. For those studying drug allergy ; 3. Persons with coagulation disorders ; 4. Persons with cognitive impairment who cannot cooperate ; 5. pregnant or lactating women with mental and nervous system diseases ; 6. Always taking other analgesics.

Design outcomes

Primary

Measure	Time frame
pain scale;	—

Secondary

Measure	Time frame
Cluster of differentiation 8;SF-36 scale;Cluster of differentiation 4;SP;IL-6;TNF-a;MCP-1;5-HT;ß-Endorphin;Cluster of differentiation 3;chinese medicine syndrome scores;Pittsurgh sleep quality in-dex;	—

Countries

China

Contacts

Public ContactWang Jian

wangjianj7@126.com15965622883

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026